melatonin has been researched along with Amentia in 43 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Forty-four participants with DSM-IV diagnoses of dementia with sleep disturbance were selected for a seven week randomised double blind cross over trial of slow release melatonin 6 mg versus placebo." | 9.10 | Double blind randomised placebo controlled trial of low dose melatonin for sleep disorders in dementia. ( Blizard, R; Kennell-Webb, S; Raven, P; Serfaty, M; Warner, J, 2002) |
| "The purpose of this study was to evaluate the effects of bright light therapy combined with melatonin on motor restless behaviour in dementia." | 9.09 | Bright light therapy and melatonin in motor restless behaviour in dementia: a placebo-controlled study. ( Cats, Q; Haffmans, PM; Lucius, SA; Sival, RC; van Gelder, L, 2001) |
| "The current review aims to examine melatonin therapy for both sleep disturbances and cognitive function in dementia." | 8.91 | Melatonin for sleep disorders and cognition in dementia: a meta-analysis of randomized controlled trials. ( Chen, SD; Dammer, EB; Li, CB; Wang, G; Wang, LL; Xu, G; Xu, J, 2015) |
| " All papers on melatonin treatment in dementia were retrieved." | 8.86 | Effectiveness of melatonin treatment on circadian rhythm disturbances in dementia. Are there implications for delirium? A systematic review. ( de Jonghe, A; de Rooij, SE; Korevaar, JC; van Munster, BC, 2010) |
| " This study explored the association between clinical markers and 1) dim light melatonin onset (DLMO) time and 2) phase angle derived from sleep midpoint, in older adults with varying dementia risks." | 8.31 | Actigraphic and melatonin alignment in older adults with varying dementia risk. ( Gordon, CJ; Hickie, I; Hoyos, CM; Lewis, SJ; Menczel Schrire, Z; Murray, J; Naismith, SL; Palmer, JR; Pye, JE; Rogers, NL; Terpening, Z, 2023) |
| "The present work aimed to investigate the induction of circadian rhythm dysfunction and dementia upon chronic exposure to light-light and its reversal by melatonin in Wistar rats." | 8.12 | Chronic Light-Distorted Glutamate-Cortisol Signaling, Behavioral and Histological Markers, and Induced Oxidative Stress and Dementia: An Amelioration by Melatonin. ( Aljabali, AAA; Chellappan, DK; Dua, K; Goyal, R; Sarena, P; Sharma, A; Taliyan, R; Tambuwala, MM; Urmera, MT, 2022) |
| "A recent study in the JAMA described the effects of long-term daily treatment with whole-day bright light in elderly patients with dementia, with or without the addition of melatonin (2." | 7.74 | [Symptomatic treatment in patients with dementia: light, but not melatonin, is probably worthwhile]. ( van Marum, RJ, 2008) |
| "The daily rhythm in serum melatonin levels was measured in patients with dementia of the degenerate type (Alzheimer's disease, Pick's disease and senile dementia of the Alzheimer type) by radioimmunoassay." | 7.69 | Daily rhythm of serum melatonin in patients with dementia of the degenerate type. ( Morita, Y; Ohara, K; Okamoto, N; Uchida, K, 1996) |
| "Melatonin levels have been shown to decline with aging." | 6.53 | Melatonin based therapies for delirium and dementia. ( Alagiakrishnan, K, 2016) |
| " Chronic administration of melatonin (0." | 5.31 | Possible antioxidant mechanism in melatonin reversal of aging and chronic ethanol-induced amnesia in plus-maze and passive avoidance memory tasks. ( Kulkarni, SK; Raghavendra, V, 2001) |
| "Forty-four participants with DSM-IV diagnoses of dementia with sleep disturbance were selected for a seven week randomised double blind cross over trial of slow release melatonin 6 mg versus placebo." | 5.10 | Double blind randomised placebo controlled trial of low dose melatonin for sleep disorders in dementia. ( Blizard, R; Kennell-Webb, S; Raven, P; Serfaty, M; Warner, J, 2002) |
| "The purpose of this study was to evaluate the effects of bright light therapy combined with melatonin on motor restless behaviour in dementia." | 5.09 | Bright light therapy and melatonin in motor restless behaviour in dementia: a placebo-controlled study. ( Cats, Q; Haffmans, PM; Lucius, SA; Sival, RC; van Gelder, L, 2001) |
| "The current review aims to examine melatonin therapy for both sleep disturbances and cognitive function in dementia." | 4.91 | Melatonin for sleep disorders and cognition in dementia: a meta-analysis of randomized controlled trials. ( Chen, SD; Dammer, EB; Li, CB; Wang, G; Wang, LL; Xu, G; Xu, J, 2015) |
| " All papers on melatonin treatment in dementia were retrieved." | 4.86 | Effectiveness of melatonin treatment on circadian rhythm disturbances in dementia. Are there implications for delirium? A systematic review. ( de Jonghe, A; de Rooij, SE; Korevaar, JC; van Munster, BC, 2010) |
| "There are a number of studies that suggest a relationship between decline of melatonin function and the symptoms of dementia." | 4.83 | Melatonin for cognitive impairment. ( Duncan, V; Forbes, DA; Jansen, SL; Morgan, DG, 2006) |
| " This study explored the association between clinical markers and 1) dim light melatonin onset (DLMO) time and 2) phase angle derived from sleep midpoint, in older adults with varying dementia risks." | 4.31 | Actigraphic and melatonin alignment in older adults with varying dementia risk. ( Gordon, CJ; Hickie, I; Hoyos, CM; Lewis, SJ; Menczel Schrire, Z; Murray, J; Naismith, SL; Palmer, JR; Pye, JE; Rogers, NL; Terpening, Z, 2023) |
| "The present work aimed to investigate the induction of circadian rhythm dysfunction and dementia upon chronic exposure to light-light and its reversal by melatonin in Wistar rats." | 4.12 | Chronic Light-Distorted Glutamate-Cortisol Signaling, Behavioral and Histological Markers, and Induced Oxidative Stress and Dementia: An Amelioration by Melatonin. ( Aljabali, AAA; Chellappan, DK; Dua, K; Goyal, R; Sarena, P; Sharma, A; Taliyan, R; Tambuwala, MM; Urmera, MT, 2022) |
| " Elevated plasma homocysteine is a risk factor for atherosclerosis and Alzheimer's disease, and the marked decline in adenosyl methionine with aging leads to dysregulation of methionine metabolism and hyperhomocysteinemia." | 3.88 | ( McCully, KS, 2018) |
| "A recent study in the JAMA described the effects of long-term daily treatment with whole-day bright light in elderly patients with dementia, with or without the addition of melatonin (2." | 3.74 | [Symptomatic treatment in patients with dementia: light, but not melatonin, is probably worthwhile]. ( van Marum, RJ, 2008) |
| "The daily rhythm in serum melatonin levels was measured in patients with dementia of the degenerate type (Alzheimer's disease, Pick's disease and senile dementia of the Alzheimer type) by radioimmunoassay." | 3.69 | Daily rhythm of serum melatonin in patients with dementia of the degenerate type. ( Morita, Y; Ohara, K; Okamoto, N; Uchida, K, 1996) |
| "Adult patients with a cancer diagnosis who are admitted to the palliative care unit will be randomized into a treatment or placebo group." | 2.82 | The preventative role of exogenous melatonin administration to patients with advanced cancer who are at risk of delirium: study protocol for a randomized controlled trial. ( Agar, M; Bush, SH; Currow, DC; Lacaze-Masmonteil, N; Lawlor, PG; MacDonald, AR; McNamara-Kilian, MT; Momoli, F; Tierney, S, 2016) |
| "Melatonin plays a major role in maintaining circadian rhythm." | 2.53 | Physiological melatonin levels in healthy older people: A systematic review. ( de Rooij, SE; Scholtens, RM; van Kempen, MF; van Munster, BC, 2016) |
| "Melatonin levels have been shown to decline with aging." | 2.53 | Melatonin based therapies for delirium and dementia. ( Alagiakrishnan, K, 2016) |
| "Circadian rhythm sleep disorders are caused by the disturbance of sleep-wake regulation in the central nervous system, disturbed input into the sensory organs, and decreased social activities." | 2.50 | [Sleep problems in dementia]. ( Oka, Y, 2014) |
| "The features of apoptotic dose responses typically have been evaluated over a broad dose-response continuum to differentiate apoptotic and necrotic responses." | 2.41 | Apoptosis: biphasic dose responses. ( Calabrese, EJ, 2001) |
| "Prevention of dementia is important, because it is a leading cause of disability in elderly people." | 1.91 | Effects of endogenous and exogenous N-acetyl-5-methoxy kynuramine on object recognition memory in male C3H mice. ( Chiba, A; Iwashita, H; Sano, M, 2023) |
| "Melatonin is an endogenous pleiotropic molecule which orchestrates regulatory functions and protective capacity against age-related ailments." | 1.48 | Melatonin induces mechanisms of brain resilience against neurodegeneration. ( Cardoso, BR; Corpas, R; Franciscato Cozzolino, SM; García de Frutos, P; Griñán-Ferré, C; Pallàs, M; Palomera-Ávalos, V; Porquet, D; Rodríguez-Farré, E; Sanfeliu, C, 2018) |
| "Treatment of circadian rhythm disorders has led to the development of a new type of agent called "chronobiotics," among which melatonin is the prototype." | 1.33 | Clinical perspectives for the use of melatonin as a chronobiotic and cytoprotective agent. ( Cardinali, DP; Furio, AM; Reyes, MP, 2005) |
| " Chronic administration of melatonin (0." | 1.31 | Possible antioxidant mechanism in melatonin reversal of aging and chronic ethanol-induced amnesia in plus-maze and passive avoidance memory tasks. ( Kulkarni, SK; Raghavendra, V, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (6.98) | 18.7374 |
| 1990's | 5 (11.63) | 18.2507 |
| 2000's | 16 (37.21) | 29.6817 |
| 2010's | 15 (34.88) | 24.3611 |
| 2020's | 4 (9.30) | 2.80 |
| Authors | Studies |
|---|---|
| Sarena, P | 1 |
| Sharma, A | 1 |
| Urmera, MT | 1 |
| Tambuwala, MM | 1 |
| Aljabali, AAA | 1 |
| Chellappan, DK | 1 |
| Dua, K | 1 |
| Taliyan, R | 1 |
| Goyal, R | 1 |
| Menczel Schrire, Z | 3 |
| Gordon, CJ | 3 |
| Palmer, JR | 3 |
| Murray, J | 3 |
| Hickie, I | 3 |
| Rogers, NL | 3 |
| Lewis, SJ | 3 |
| Terpening, Z | 3 |
| Pye, JE | 3 |
| Naismith, SL | 3 |
| Hoyos, CM | 3 |
| Iwashita, H | 1 |
| Sano, M | 1 |
| Chiba, A | 1 |
| Iranzo, A | 1 |
| Ramos, LA | 1 |
| Novo, S | 1 |
| Münch, M | 1 |
| Schmieder, M | 1 |
| Bieler, K | 1 |
| Goldbach, R | 1 |
| Fuhrmann, T | 1 |
| Zumstein, N | 1 |
| Vonmoos, P | 1 |
| Scartezzini, JL | 1 |
| Wirz-Justice, A | 1 |
| Cajochen, C | 1 |
| McCully, KS | 1 |
| Corpas, R | 1 |
| Griñán-Ferré, C | 1 |
| Palomera-Ávalos, V | 1 |
| Porquet, D | 1 |
| García de Frutos, P | 1 |
| Franciscato Cozzolino, SM | 1 |
| Rodríguez-Farré, E | 1 |
| Pallàs, M | 1 |
| Sanfeliu, C | 1 |
| Cardoso, BR | 1 |
| Park, J | 1 |
| Han, JW | 1 |
| Lee, JR | 1 |
| Byun, S | 1 |
| Suh, SW | 1 |
| Kim, T | 1 |
| Yoon, IY | 1 |
| Kim, KW | 1 |
| Gardner, C | 1 |
| Xu, J | 1 |
| Wang, LL | 1 |
| Dammer, EB | 1 |
| Li, CB | 1 |
| Xu, G | 1 |
| Chen, SD | 1 |
| Wang, G | 1 |
| Oka, Y | 1 |
| Hu, K | 1 |
| Riemersma-van der Lek, RF | 3 |
| Patxot, M | 1 |
| Li, P | 1 |
| Shea, SA | 1 |
| Scheer, FA | 1 |
| Van Someren, EJ | 2 |
| Scholtens, RM | 1 |
| van Munster, BC | 2 |
| van Kempen, MF | 1 |
| de Rooij, SE | 2 |
| Alagiakrishnan, K | 1 |
| Bush, SH | 1 |
| Lacaze-Masmonteil, N | 1 |
| McNamara-Kilian, MT | 1 |
| MacDonald, AR | 1 |
| Tierney, S | 1 |
| Momoli, F | 1 |
| Agar, M | 1 |
| Currow, DC | 1 |
| Lawlor, PG | 1 |
| Pillai, JA | 1 |
| Leverenz, JB | 1 |
| Swaab, DF | 2 |
| Twisk, J | 2 |
| Hol, EM | 2 |
| Hoogendijk, WJ | 2 |
| van Marum, RJ | 1 |
| van Someren, EW | 1 |
| Arushanian, EB | 1 |
| de Jonghe, A | 1 |
| Korevaar, JC | 1 |
| Bedrosian, TA | 1 |
| Herring, KL | 1 |
| Weil, ZM | 1 |
| Nelson, RJ | 1 |
| Serfaty, M | 1 |
| Kennell-Webb, S | 1 |
| Warner, J | 1 |
| Blizard, R | 1 |
| Raven, P | 1 |
| Serrano, C | 1 |
| García-Borreguero, D | 1 |
| Reiter, RJ | 1 |
| Tan, DX | 1 |
| Pappolla, MA | 1 |
| Cardinali, DP | 1 |
| Furio, AM | 1 |
| Reyes, MP | 1 |
| Jansen, SL | 1 |
| Forbes, DA | 1 |
| Duncan, V | 1 |
| Morgan, DG | 1 |
| Wolkove, N | 1 |
| Elkholy, O | 1 |
| Baltzan, M | 1 |
| Palayew, M | 1 |
| Mahlberg, R | 1 |
| Walther, S | 1 |
| Touitou, Y | 2 |
| Fèvre, M | 2 |
| Bogdan, A | 2 |
| Reinberg, A | 2 |
| De Prins, J | 1 |
| Beck, H | 2 |
| Touitou, C | 2 |
| Lagoguey, M | 1 |
| Carayon, A | 1 |
| Cesselin, F | 1 |
| Sandyk, R | 1 |
| Iacono, RP | 1 |
| Uchida, K | 1 |
| Okamoto, N | 1 |
| Ohara, K | 1 |
| Morita, Y | 1 |
| McGaffigan, S | 1 |
| Bliwise, DL | 1 |
| Magri, F | 1 |
| Locatelli, M | 1 |
| Balza, G | 1 |
| Molla, G | 1 |
| Cuzzoni, G | 1 |
| Fioravanti, M | 1 |
| Solerte, SB | 1 |
| Ferrari, E | 1 |
| Mishima, K | 1 |
| Okawa, M | 1 |
| Hozumi, S | 1 |
| Hishikawa, Y | 1 |
| Haffmans, PM | 1 |
| Sival, RC | 1 |
| Lucius, SA | 1 |
| Cats, Q | 1 |
| van Gelder, L | 1 |
| Raghavendra, V | 1 |
| Kulkarni, SK | 1 |
| Luboshitzky, R | 1 |
| Shen-Orr, Z | 1 |
| Tzischichinsky, O | 1 |
| Maldonado, M | 1 |
| Herer, P | 1 |
| Lavie, P | 1 |
| Calabrese, EJ | 1 |
| Maurizi, CP | 1 |
| Souêtre, E | 1 |
| Salvati, E | 1 |
| Krebs, B | 1 |
| Belugou, JL | 1 |
| Darcourt, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Placebo-controlled Trial Evaluating the Effect of Melatonin on Sleep Quality in Patients With Dementia[NCT03066518] | Phase 4 | 40 participants (Actual) | Interventional | 2016-01-15 | Completed | ||
| Multicenter Randomized Controlled Trial of the Efficacy of Melatonin in the Prophylaxis of SARS-coronavirus-2 Infection Among High Risk Contacts.[NCT04353128] | Phase 2/Phase 3 | 450 participants (Actual) | Interventional | 2020-04-20 | Completed | ||
| The Preventative Role of Exogenous Melatonin Administration in Patients With Advanced Cancer Who Are at Risk of Delirium: a Feasibility Study Prior to a Larger Randomized Controlled Trial[NCT02200172] | Phase 2 | 60 participants (Actual) | Interventional | 2014-12-31 | Completed | ||
| Light Therapy in Parkinson's Disease: a Prospective, Observational Study[NCT06129942] | 50 participants (Anticipated) | Interventional | 2021-09-01 | Recruiting | |||
| Dynamic Light Application to Prevent ICU Acquired Delirium[NCT01274819] | 1,000 participants (Actual) | Interventional | 2011-07-31 | Completed | |||
| Exploratory Study of Melatonin Induced Sleep Regularization in Severe Brain Injury[NCT02732288] | 1 participants (Actual) | Interventional | 2016-05-31 | Terminated (stopped due to Interrupted by Covid-19) | |||
| Prevention of Delirium in Inpatients Utilizing Melatonin[NCT02654314] | Phase 3 | 277 participants (Actual) | Interventional | 2016-07-31 | Terminated (stopped due to Lack of resources to complete the study. Descriptive statistics for the outcome measures collected are provided.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Days utilizing restraints is defined as the number of days restraints were applied because of delirium in the first 14 days of hospitalization. (NCT02654314)
Timeframe: length of hospitalization, not to exceed 14 days
| Intervention | days (Median) |
|---|---|
| Melatonin | 0 |
| Cellulose Microcrystylline | 0 |
Delirium is defined by the Short Form Confusion Assessment Method (CAM). There must be inattention and either an acute or fluctuating course plus either disorganized thinking or an altered level of consciousness to be diagnosed with delirium. Presented is a count of individuals with reported delirium during hospitalization. (NCT02654314)
Timeframe: length of hospitalization, not to exceed 14 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Melatonin | 2 |
| Cellulose Microcrystylline | 8 |
Length of stay is defined as the total time hospitalized for the acute illness (in days). (NCT02654314)
Timeframe: from day of admission to completion of acute care, not to exceed 30 days
| Intervention | days (Mean) |
|---|---|
| Melatonin | 4.58 |
| Cellulose Microcrystylline | 4.71 |
Number of delirium anti-psychotic drug doses given for symptoms of delirium. Presented are the number of doses per days of hospitalization. (NCT02654314)
Timeframe: length of hospitalization, not to exceed 14 days
| Intervention | number of doses per days of hospitalizat (Median) |
|---|---|
| Melatonin | 0 |
| Cellulose Microcrystylline | 0 |
15 reviews available for melatonin and Amentia
| Article | Year |
|---|---|
The Isolated Form of Rapid Eye Movement Sleep Behavior Disorder: The Upcoming Challenges.
Topics: Clonazepam; Dementia; Diagnostic Tests, Routine; Humans; Melatonin; Parkinson Disease; REM Sleep Beh | 2021 |
Melatonin for sleep disorders and cognition in dementia: a meta-analysis of randomized controlled trials.
Topics: Alzheimer Disease; Central Nervous System Depressants; Cognition; Cognition Disorders; Dementia; Dem | 2015 |
[Sleep problems in dementia].
Topics: Aged; Aged, 80 and over; Aging; Chronobiology Disorders; Circadian Rhythm; Dementia; Humans; Melaton | 2014 |
Physiological melatonin levels in healthy older people: A systematic review.
Topics: Aged; Aged, 80 and over; Aging; Circadian Rhythm; Dementia; Dietary Supplements; Female; Health Stat | 2016 |
Melatonin based therapies for delirium and dementia.
Topics: Aged; Animals; Antipsychotic Agents; Benzodiazepines; Chronobiology Phenomena; Clinical Trials as To | 2016 |
Sleep and Neurodegeneration: A Critical Appraisal.
Topics: Alzheimer Disease; Dementia; Humans; Lewy Body Disease; Melatonin; Multiple System Atrophy; Neurodeg | 2017 |
[A hormonal drug melatonin in the treatment of cognitive function disorders in parkinsonism].
Topics: Cognition Disorders; Corpus Striatum; Dementia; Humans; Melatonin; Neuroprotective Agents; Nootropic | 2010 |
Effectiveness of melatonin treatment on circadian rhythm disturbances in dementia. Are there implications for delirium? A systematic review.
Topics: Aged; Aged, 80 and over; Central Nervous System Depressants; Circadian Rhythm; Delirium; Dementia; F | 2010 |
Effectiveness of melatonin treatment on circadian rhythm disturbances in dementia. Are there implications for delirium? A systematic review.
Topics: Aged; Aged, 80 and over; Central Nervous System Depressants; Circadian Rhythm; Delirium; Dementia; F | 2010 |
Effectiveness of melatonin treatment on circadian rhythm disturbances in dementia. Are there implications for delirium? A systematic review.
Topics: Aged; Aged, 80 and over; Central Nervous System Depressants; Circadian Rhythm; Delirium; Dementia; F | 2010 |
Effectiveness of melatonin treatment on circadian rhythm disturbances in dementia. Are there implications for delirium? A systematic review.
Topics: Aged; Aged, 80 and over; Central Nervous System Depressants; Circadian Rhythm; Delirium; Dementia; F | 2010 |
Fluctuations in cognition and alertness in Parkinson's disease and dementia.
Topics: Awareness; Central Nervous System Stimulants; Cholinesterase Inhibitors; Cognition Disorders; Dement | 2004 |
Melatonin relieves the neural oxidative burden that contributes to dementias.
Topics: Animals; Antioxidants; Apoptosis; Dementia; Free Radical Scavengers; Humans; Melatonin; Neurons; Oxi | 2004 |
Melatonin for cognitive impairment.
Topics: Antioxidants; Cognition Disorders; Dementia; Humans; Melatonin; Randomized Controlled Trials as Topi | 2006 |
Sleep and aging: 2. Management of sleep disorders in older people.
Topics: Adjuvants, Immunologic; Aged; Aging; Antidepressive Agents; Behavior Therapy; Benzodiazepines; Demen | 2007 |
The treatment of sundowning. A selective review of pharmacological and nonpharmacological studies.
Topics: Antipsychotic Agents; Chlormethiazole; Clozapine; Dementia; Humans; Melatonin; Phototherapy; Psychom | 1997 |
Supplementary administration of artificial bright light and melatonin as potent treatment for disorganized circadian rest-activity and dysfunctional autonomic and neuroendocrine systems in institutionalized demented elderly persons.
Topics: Aged; Circadian Rhythm; Dementia; Humans; Institutionalization; Melatonin; Neurosecretory Systems; P | 2000 |
Apoptosis: biphasic dose responses.
Topics: Animals; Antioxidants; Apoptosis; Cycloheximide; Dementia; Dimethylformamide; Dose-Response Relation | 2001 |
6 trials available for melatonin and Amentia
| Article | Year |
|---|---|
Progression of Dementia Assessed by Temporal Correlations of Physical Activity: Results From a 3.5-Year, Longitudinal Randomized Controlled Trial.
Topics: Aged; Aged, 80 and over; Circadian Rhythm; Dementia; Disease Progression; Double-Blind Method; Exerc | 2016 |
The preventative role of exogenous melatonin administration to patients with advanced cancer who are at risk of delirium: study protocol for a randomized controlled trial.
Topics: Central Nervous System Agents; Clinical Protocols; Dementia; Double-Blind Method; Feasibility Studie | 2016 |
Effect of bright light and melatonin on cognitive and noncognitive function in elderly residents of group care facilities: a randomized controlled trial.
Topics: Activities of Daily Living; Affect; Aged, 80 and over; Circadian Rhythm; Cognition; Combined Modalit | 2008 |
Effect of bright light and melatonin on cognitive and noncognitive function in elderly residents of group care facilities: a randomized controlled trial.
Topics: Activities of Daily Living; Affect; Aged, 80 and over; Circadian Rhythm; Cognition; Combined Modalit | 2008 |
Effect of bright light and melatonin on cognitive and noncognitive function in elderly residents of group care facilities: a randomized controlled trial.
Topics: Activities of Daily Living; Affect; Aged, 80 and over; Circadian Rhythm; Cognition; Combined Modalit | 2008 |
Effect of bright light and melatonin on cognitive and noncognitive function in elderly residents of group care facilities: a randomized controlled trial.
Topics: Activities of Daily Living; Affect; Aged, 80 and over; Circadian Rhythm; Cognition; Combined Modalit | 2008 |
Effect of bright light and melatonin on cognitive and noncognitive function in elderly residents of group care facilities: a randomized controlled trial.
Topics: Activities of Daily Living; Affect; Aged, 80 and over; Circadian Rhythm; Cognition; Combined Modalit | 2008 |
Effect of bright light and melatonin on cognitive and noncognitive function in elderly residents of group care facilities: a randomized controlled trial.
Topics: Activities of Daily Living; Affect; Aged, 80 and over; Circadian Rhythm; Cognition; Combined Modalit | 2008 |
Effect of bright light and melatonin on cognitive and noncognitive function in elderly residents of group care facilities: a randomized controlled trial.
Topics: Activities of Daily Living; Affect; Aged, 80 and over; Circadian Rhythm; Cognition; Combined Modalit | 2008 |
Effect of bright light and melatonin on cognitive and noncognitive function in elderly residents of group care facilities: a randomized controlled trial.
Topics: Activities of Daily Living; Affect; Aged, 80 and over; Circadian Rhythm; Cognition; Combined Modalit | 2008 |
Effect of bright light and melatonin on cognitive and noncognitive function in elderly residents of group care facilities: a randomized controlled trial.
Topics: Activities of Daily Living; Affect; Aged, 80 and over; Circadian Rhythm; Cognition; Combined Modalit | 2008 |
Double blind randomised placebo controlled trial of low dose melatonin for sleep disorders in dementia.
Topics: Aged; Aged, 80 and over; Cross-Over Studies; Delayed-Action Preparations; Dementia; Double-Blind Met | 2002 |
Actigraphy in agitated patients with dementia. Monitoring treatment outcomes.
Topics: Aged; Aged, 80 and over; Dementia; Dronabinol; Female; Humans; Male; Melatonin; Middle Aged; Monitor | 2007 |
Bright light therapy and melatonin in motor restless behaviour in dementia: a placebo-controlled study.
Topics: Aged; Aggression; Anticonvulsants; Combined Modality Therapy; Cross-Over Studies; Dementia; Double-B | 2001 |
22 other studies available for melatonin and Amentia
| Article | Year |
|---|---|
Chronic Light-Distorted Glutamate-Cortisol Signaling, Behavioral and Histological Markers, and Induced Oxidative Stress and Dementia: An Amelioration by Melatonin.
Topics: Animals; Biomarkers; Circadian Rhythm; Dementia; Dextromethorphan; Glutamic Acid; Hydrocortisone; Li | 2022 |
Actigraphic and melatonin alignment in older adults with varying dementia risk.
Topics: Actigraphy; Aged; Circadian Rhythm; Dementia; Humans; Light; Male; Melatonin; Sleep | 2023 |
Actigraphic and melatonin alignment in older adults with varying dementia risk.
Topics: Actigraphy; Aged; Circadian Rhythm; Dementia; Humans; Light; Male; Melatonin; Sleep | 2023 |
Actigraphic and melatonin alignment in older adults with varying dementia risk.
Topics: Actigraphy; Aged; Circadian Rhythm; Dementia; Humans; Light; Male; Melatonin; Sleep | 2023 |
Actigraphic and melatonin alignment in older adults with varying dementia risk.
Topics: Actigraphy; Aged; Circadian Rhythm; Dementia; Humans; Light; Male; Melatonin; Sleep | 2023 |
Actigraphic and melatonin alignment in older adults with varying dementia risk.
Topics: Actigraphy; Aged; Circadian Rhythm; Dementia; Humans; Light; Male; Melatonin; Sleep | 2023 |
Actigraphic and melatonin alignment in older adults with varying dementia risk.
Topics: Actigraphy; Aged; Circadian Rhythm; Dementia; Humans; Light; Male; Melatonin; Sleep | 2023 |
Actigraphic and melatonin alignment in older adults with varying dementia risk.
Topics: Actigraphy; Aged; Circadian Rhythm; Dementia; Humans; Light; Male; Melatonin; Sleep | 2023 |
Actigraphic and melatonin alignment in older adults with varying dementia risk.
Topics: Actigraphy; Aged; Circadian Rhythm; Dementia; Humans; Light; Male; Melatonin; Sleep | 2023 |
Actigraphic and melatonin alignment in older adults with varying dementia risk.
Topics: Actigraphy; Aged; Circadian Rhythm; Dementia; Humans; Light; Male; Melatonin; Sleep | 2023 |
Effects of endogenous and exogenous N-acetyl-5-methoxy kynuramine on object recognition memory in male C3H mice.
Topics: Animals; Antioxidants; Dementia; Kynuramine; Male; Melatonin; Mice; Mice, Inbred C3H; Mice, Inbred I | 2023 |
Bright Light Delights: Effects of Daily Light Exposure on Emotions, Restactivity Cycles, Sleep and Melatonin Secretion in Severely Demented Patients.
Topics: Aged; Aged, 80 and over; Circadian Rhythm; Cohort Studies; Dementia; Emotions; Female; Humans; Light | 2017 |
Topics: Atherosclerosis; Dementia; Homocysteine; Humans; Hyperhomocysteinemia; Melatonin; Mitochondria; Oxid | 2018 |
Melatonin induces mechanisms of brain resilience against neurodegeneration.
Topics: Animals; Blotting, Western; Brain; Cognition; Dementia; Intercellular Signaling Peptides and Protein | 2018 |
Lifetime coffee consumption, pineal gland volume, and sleep quality in late life.
Topics: Aged; Aged, 80 and over; Caffeine; Coffee; Cognition; Dementia; Female; Humans; Imaging, Three-Dimen | 2018 |
Creating the right light for older people.
Topics: Aged; Circadian Rhythm; Dementia; Equipment Design; Humans; Lighting; Melatonin; Phototherapy; Seaso | 2014 |
[Symptomatic treatment in patients with dementia: light, but not melatonin, is probably worthwhile].
Topics: Affect; Aged; Aged, 80 and over; Cognition; Dementia; Depression; Female; Humans; Male; Melatonin; P | 2008 |
Brighter daytime lighting may improve dementia.
Topics: Antioxidants; Dementia; Female; Homes for the Aged; Humans; Lighting; Male; Melatonin; Nursing Homes | 2008 |
[Symptomatic treatment of patients with dementia: light, but not melatonin, is probably worthwhile].
Topics: Dementia; Evidence-Based Medicine; Humans; Melatonin; Phototherapy | 2008 |
Altered temporal patterns of anxiety in aged and amyloid precursor protein (APP) transgenic mice.
Topics: Aging; Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Anxiety; Basal Nucleus of Meynert | 2011 |
Clinical perspectives for the use of melatonin as a chronobiotic and cytoprotective agent.
Topics: Aging; Animals; Biological Clocks; Chronobiology Disorders; Circadian Rhythm; Dementia; Humans; Mela | 2005 |
Patterns of plasma melatonin with ageing and mental condition: stability of nyctohemeral rhythms and differences in seasonal variations.
Topics: Adult; Age Factors; Aged; Aging; Circadian Rhythm; Dementia; Female; Humans; Male; Melatonin; Middle | 1984 |
Age- and mental health-related circadian rhythms of plasma levels of melatonin, prolactin, luteinizing hormone and follicle-stimulating hormone in man.
Topics: Adult; Age Factors; Aged; Circadian Rhythm; Dementia; Female; Follicle Stimulating Hormone; Humans; | 1981 |
Rapid improvement of visuoperceptive functions by picoTesla range magnetic fields in patients with Parkinson's disease.
Topics: Dementia; Dopamine; Electromagnetic Fields; Humans; Male; Melatonin; Middle Aged; Parkinson Disease; | 1993 |
Daily rhythm of serum melatonin in patients with dementia of the degenerate type.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Circadian Rhythm; Dementia; Female; Humans; Male; Melato | 1996 |
Changes in endocrine circadian rhythms as markers of physiological and pathological brain aging.
Topics: Adrenocorticotropic Hormone; Adult; Aged; Aged, 80 and over; Aging; Brain; Circadian Rhythm; Dementi | 1997 |
Possible antioxidant mechanism in melatonin reversal of aging and chronic ethanol-induced amnesia in plus-maze and passive avoidance memory tasks.
Topics: Aging; Alzheimer Disease; Amnesia; Animals; Antioxidants; Avoidance Learning; Data Interpretation, S | 2001 |
Actigraphic sleep-wake patterns and urinary 6-sulfatoxymelatonin excretion in patients with Alzheimer's disease.
Topics: Adult; Aged; Aging; Alzheimer Disease; Circadian Rhythm; Dementia; Female; Humans; Light; Male; Mela | 2001 |
The therapeutic potential for tryptophan and melatonin: possible roles in depression, sleep, Alzheimer's disease and abnormal aging.
Topics: Aging; Animals; Bipolar Disorder; Dementia; Depressive Disorder; Humans; Melatonin; Mental Disorders | 1990 |
Abnormal melatonin response to 5-methoxypsoralen in dementia.
Topics: Adult; Aged; Aging; Dementia; Depressive Disorder; Female; Furocoumarins; Humans; Male; Melatonin; M | 1989 |